Study of RA101495 in Paroxysmal Nocturnal Haemoglobinuria (PNH)

Study of RA101495 in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Registry ID

EUCTR2016-003522-16

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Ra Pharmaceuticals, Inc.

Start date

2017-05-01

Completion date

2018-03-23

Last update

2026-08-16

Conditions

• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Paroxysmal Nocturnal Haemoglobinuria (PNH)

Summary

• To assess the safety and tolerability of RA101495 in subjects with PNH • To assess preliminary efficacy of RA101495 in subjects with PNH • To assess PK and PD of RA101495 in subjects with PNH

Locations

• , , UK
• , , Finland
• , , Hungary
• , , Denmark

Related clinical trials

• Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
• A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
• Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
• A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
• REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria
• Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

View on source registry